` VTVT (vTv Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

VTVT
vs
S&P 500

Over the past 12 months, VTVT has underperformed S&P 500, delivering a return of -17% compared to the S&P 500's 9% growth.

Stocks Performance
VTVT vs S&P 500

Loading
VTVT
S&P 500
Add Stock

Performance Gap
VTVT vs S&P 500

Performance Gap Between VTVT and GSPC
HIDDEN
Show

Performance By Year
VTVT vs S&P 500

Loading
VTVT
S&P 500
Add Stock

Competitors Performance
vTv Therapeutics Inc vs Peers

S&P 500
VTVT
ABBV
AMGN
GILD
VRTX
Add Stock

vTv Therapeutics Inc
Glance View

Market Cap
50m USD
Industry
Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

VTVT Intrinsic Value
HIDDEN
Show
Back to Top